Musings about the Impact of Ecofactor and its Progeny on Patent and Trade Secret Damages

Overview

I. Introduction

The Federal Circuit’s decisions in EcoFactor v. Google (en banc 2025)[1], Jiaxing Super Lighting v. CH Lighting (2025)[2], and Rex Medical v. Intuitive Surgical (2025)[3] collectively reinforce a stricter application of Federal Rule of Evidence 702 to damages experts. While they do not alter existing damages law, they significantly tighten the evidentiary threshold for admissibility - particularly when experts rely on settlement agreements, portfolio‑level licenses, or apportionment assumptions unsupported by concrete facts.

These cases respond to recurrent problems: reliance on inferred royalty rates, apportionment without evidence, and portfolio licenses offered as comparables without allocation. They also reflect increasing concern over large jury verdicts and inconsistent gatekeeping across favored patent venues. The Federal Circuit’s directive is clear: district courts must rigorously assess factual sufficiency before letting damages theories reach the jury.

II. EcoFactor: Requirement of Mutual or Documented Royalty Evidence

A. Background

EcoFactor asserted a single smart‑thermostat patent and relied on three lump‑sum settlement agreements (Daikin, Schneider, Johnson). Each agreement stated that EcoFactor believed the lump‑sum corresponded to an “$X/unit” royalty - but also explicitly said the sum was not a royalty and not based on sales. EcoFactor offered no sales data, no negotiation records, and no licensee testimony. Its CEO testified only to a “general understanding” that $X/unit reflected the parties’ intentions. The expert adopted this rate. The jury awarded $20 million.

B. En Banc Holding

The Federal Circuit reversed:

1. Unilateral belief on reasonable rate is NOT evidence.
   EcoFactor’s self‑serving statement could not establish a mutually agreed rate.
2. General recollection on what is reasonable in the industry is NOT factual basis.
   Unsupported testimony cannot substitute for documents or contemporaneous data.
3. Rule 702 requires evaluating factual sufficiency at admissibility, NOT weight.
   Courts must exclude opinions lacking evidentiary grounding.
4. Settlement agreements remain usable - but ONLY with corroborating evidence.
   Experts must show that the rate was mutually agreed or independently supported.

C. Significance

EcoFactor significantly limits the use of settlement agreements to infer royalty rates. Experts must present actual evidence connecting lump‑sum payments to per‑unit rates. Uncorroborated impressions or inferred arithmetic no longer suffice.

III. Jiaxing: Rejecting Qualitative Adjustments as Apportionment

A. Background

Jiaxing’s expert relied on two portfolio‑level licenses (TCP and Lunera) and attempted to apportion their portfolio‑wide rates to three asserted LED patents by asserting certain patents “drove” negotiations and applying qualitative upward/downward adjustments.

B. Federal Circuit Holding

The court expressed concerns about admissibility under EcoFactor:

1. Apportionment requires factual evidence.
   Experts must show how specific patents contributed to negotiation value.
2. Qualitative adjustments are inadequate without data.
   “Upward for competition” or “downward for breadth” is not evidence‑based apportionment.
3. Portfolio reliance requires documented allocation.
   Experts need transaction records, negotiation evidence, licensee input, or technical valuation tying value to specific patents among the entire portfolio.

C. Significance

Jiaxing reinforces that portfolio licenses cannot be used as comparables to infer a reasonable royalty rate for specific patent(s), without quantitative, evidence‑based apportionment. Unsupported “driver patent” assertions will not survive Rule 702 scrutiny.

IV. Rex Medical: Failure to Apportion Leads to Nominal Damages

A. Background

Rex Medical relied on a $10 million portfolio settlement with a third party (Covidien), even though the ’650 patent asserted in this case had been dropped from that earlier suit against Covidien. The expert offered no evidence allocating any portion of the settlement to the ’650 patent. With the expert excluded, the jury still awarded $10 million based on lay testimony; the district court reduced damages to $1 nominal damages, and the Federal Circuit affirmed.

B. Holding

1. Apportionment is mandatory. 
   Experts may not assign portfolio‑level value to a single patent without evidence.
2. Lay testimony cannot establish damages.
   Unsupported statements about value of a patent cannot substitute for expert analysis.
3. Without admissible damages evidence, nominal damages are appropriate.

C. Significance

Rex Medical is a stark reminder: failure to apportion can eliminate damages entirely.

V. Possible Reason for Increased Scrutiny in Patent Damages Awards

One possible reason for Federal Circuit’s reversal of the large damages awards might be because the patent verdicts - particularly in EDTX and WDTX - have increasingly reached hundreds of millions or more. The Federal Circuit might have felt the need to demand higher standard for district courts’ “gatekeeping” role.

Another possibility is that the disparity between pro-patent forums and other forums has become wider. For example, six out of ten largest patent damages awards issued by jury in 2025 were returned by EDTX juries.[4] The difference in pro-patent tendencies of juries in different districts may have incurred a sense of need for check by the appellate court. In fact, EcoFactor and its progeny reflect the Federal Circuit’s demand for a shift toward front‑loaded gatekeeping: district courts must scrutinize damages opinions at the Rule 702 stage rather than rely on appellate correction.

VI. Implications for Trade Secret Damages

Recent trade‑secret cases show similar trends. Courts now require:

• apportionment of damages to the trade secret at issue (e.g., Motorola v. Hytera[5]),
• exclusion of revenue not tied to the misused secret (e.g., Appian v. Pegasystems[6]),
• damages models matching only the secrets the jury finds misappropriated out of all asserted secrets (e.g., Trinseo[7]), and
• quantitative allocation where products combine secret and non‑secret technology (In re Avaya[8]).

This suggests that EcoFactor‑style evidentiary rigor will increasingly apply in DTSA and state trade‑secret actions.

VIII. Conclusion

EcoFactor, Jiaxing, and Rex Medical impose a stricter evidentiary threshold for damages experts. Opinions must rest on:

• mutually agreed royalty rate or structure,
• quantitative apportionment, and
• a clear link to the value of the specific asserted IP.

These decisions respond to rising jury awards and reaffirm the centrality of the court’s gatekeeping function. Going forward, parties must prepare damages cases with the expectation that Rule 702 will be rigorously enforced.

Professionals

Robert Isackson

Partner

Catherine Kim

Associate